EXHIBIT 99.03 | |||
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ![]() | ||
Press Release |
20 June 2007
Shire plc AGM – 2007
Results of the Annual General Meeting
Shire plc held its Annual General Meeting today. All resolutions were put to the meeting and approved on a show of hands. The proxy votes received for the meeting are set out below:
For* | Against | Abstentions | ||
1. | To receive the Companys’ accounts for the year ended 31 December 2006 | 447,172,037 (99.86%) | 618,289 (0.14%) | 344,753 |
2. | To re-elect Dr James Henry Cavanaugh as a director | 438,104,602 (97.87%) | 9,521,491 (2.13%) | 508,986 |
3. | To re-elect Dr Barry John Price as a director | 442,879,006 (98.94%) | 4,746,232 (1.06%) | 509,841 |
4. | To elect Ms Kathleen Anne Nealon as a director | 445,691,229 (99.59%) | 1,829,400 (0.41%) | 614,450 |
5. | To elect Dr Jeffrey Marc Leiden as a director | 446,606,331 (99.84%) | 722,660 (0.16%) | 806,088 |
6. | To re-elect Mr Matthew William Emmens as a director | 443,368,069 (99.27%) | 3,263,625 (0.73%) | 1,503,385 |
7. | To re-elect Mr David John Kappler as a director | 445,342,529 (99.58%) | 1,866,620 (0.42%) | 925,930 |
8. | To re-elect Mr Patrick Jean Marc Langlois as a director | 445,769,759 (99.62%) | 1,689,983 (0.38%) | 675,337 |
9. | To re-appoint Deloitte & Touche LLP as Auditors | 443,403,135 (99.19%) | 3,642,175 (0.81%) | 1,089,769 |
10. | To authorise the Audit Committee to determine the remuneration of the Auditors | 445,398,735 (99.41%) | 2,649,952 (0.59%) | 86,392 |
11. | To approve the Directors’ Remuneration Report | 409,534,456 (92.16%) | 34,837,916 (7.84%) | 3,762,707 |
12. | To authorise the allotment of shares | 438,600,896 (98.07%) | 8,651,326 (1.93%) | 882,857 |
13. | To authorise the disapplication of pre-emption rights | 445,430,893 (99.55%) | 2,019,318 (0.45%) | 684,868 |
Registered in England 5492592 Registered Office as above
14. | To authorise market purchases | 447,306,882 (99.99%) | 60,523 (0.01%) | 767,674 |
15. | To authorise donations to EU political organisations and EU political expenditure | 442,515,165 (99.31%) | 3,095,982 (0.69%) | 2,523,932 |
16. | To approve the rules of the 2007 Shire plc Employee Stock Purchase Plan | 443,650,279 (99.29%) | 3,168,294 (0.71%) | 1,316,506 |
* These figures include discretionary votes
** Abstentions are not counted in the proportion of votes “for” or “against”
T May
Company Secretary
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 | |
Eric Rojas (North America) | +1 484 595 8252 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.